$heff's $tation of $tocks & $olid DD

[cccpmd666]

Dendreon Corp. (DNDN) said updated results for a Phase III study of its prostate-cancer drug showed it extended overall survival of men with metastatic castrate-resistant forms of the disease.
Its shares gained 2.8% to $34.55 in after-hours trading.
The data will be presented Friday at the American Society of Clinical Oncology meeting in San Francisco.
An analysis performed three years after the study began showed Provenge increased survival 40% compared with placebos and the median length of survival was more than four months.
Previously reported results, compiled 34 months after the beginning of the study, had shown the drug met its goal of "significantly improving overall survival" compared with placebos and it increased survival 38%.
Dendreon reported in April the success of Provenge in a Phase III trial--data that were necessary after the Food and Drug Administration rejected the drug in 2007 despite an advisory panel recommending approval.
The agency is expected to decide by May 1 whether to approve Provenge sales, and the company has consistently said it doesn't expect another panel would be needed in the drug's review.